MBX Stock: Price, Earnings History and SEC Filings
MBX Biosciences, Inc. (MBX) last traded at $55.87, up 2.44% on the latest session and down 4.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.78 against an analyst estimate of $-0.68, a miss of 14.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
MBX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.78 | $-0.68 | -14.71% |
| Mar 2026 | May 7, 2026 | $-0.51 | $-0.62 | +17.74% |
| Dec 2025 | Mar 12, 2026 | $-0.49 | $-0.64 | +23.44% |
| Sep 2025 | Nov 6, 2025 | $-0.63 | $-0.73 | +13.70% |
MBX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How MBX reacts to earnings
Across its last 8 earnings releases, MBX moved 5.4% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | -0.55% |
| 2026-05-07 | Before open | +8.06% |
| 2026-03-12 | Before open | -3.42% |
| 2026-01-12 | Before open | +15.19% |
| 2025-11-06 | Before open | +9.71% |
| 2025-08-07 | Before open | -4.63% |
| 2025-05-12 | Before open | +0.27% |
| 2025-03-17 | Before open | +1.72% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
MBX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$87M | -$82M | – | $-2.38 |
| 2024 | – | -$62M | -$56M | – | $-5.82 |
| 2023 | – | -$33M | -$32M | – | $-31.96 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for MBX
- 8-K · Oct 22, 2026Officer or director change, Financial statements and exhibits
- 8-K · Aug 27, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Regulation FD disclosure, Other events
- 8-K · Jul 13, 2026Officer or director change
- 8-K · Jun 12, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 5, 2026Officer or director change, Shareholder vote
- 8-K · May 11, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 7, 2026
Insider filing activity
MBX insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
MBX news
No recent headlines found. The live terminal has the full news feed.
About MBX Biosciences, Inc.
MBX Biosciences, Inc. (MBX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.